CellaVision to apply for listing on NASDAQ OMX Stockholm, Small Cap

The Board of Directors of CellaVision AB plans to apply for a listing on NASDAQ OMX Stockholm, Small Cap. The listing will increase opportunities for institutional investors to invest in CellaVision and create better share liquidity. The Board expects the listing on NASDAQ OMX Stockholm, Small Cap to take place during the first half of 2010.


“CellaVision is a sound and stable company with a good business platform making it well-positioned to be listed on NASDAQ OMX Stockholm’s Small Cap. A listing in the main market will improve opportunities to significantly broaden our investor base, increase liquidity and allow us greater freedom of action in our continued expansion”, says Lars Gatenbeck, Chairman of the Board of CellaVision.


CellaVision’s shares have been traded on First North, in the Premier segment, since May 28, 2007. Shares will continue to be traded on First North Premier until the change to NASDAQ OMX Stockholm, Small Cap has taken place.


About CellaVision

CellaVision AB develops, markets, and sells market leading image analysis based systems for routine analysis of blood and other body fluids. The company has a core competence in development of software and hardware for automatic image analysis of cells and cell changes for applications in health and medical care. The company develops and markets systems for automatic differentials of white blood cells and red morphology, and software for education and quality assurance of differentials. The company’s associates have expertise in advanced imaging analysis, artificial intelligence, and automated microscopy.


The company headquarters are in Lund, Sweden. The company also has subsidiaries in USA, Canada and Japan. For more information, visit www.cellavision.com.


CellaVision’s share is listed on First North Premier at NASDAQ OMX. The company’s Certified Advisor is Remium AB.